Advertisement

HRR Testing & PARPi Underutilized in Patients With Metastatic Prostate Cancer

Apr 11, 2024

REFERENCES & ADDITIONAL READING

  1. Vasudevan A, et al. HRR testing and PARPi utilization among patients with metastatic castration-resistant prostate cancer treated in the real-world setting. Abstract presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25-27, 2024; San Francisco, CA.
  2. Thomas RA, et al. Use of poly (adp-ribose) polymerase inhibitors (PARPi) in metastatic castration resistant prostate cancer (mCRPC) patients stratified by homologous recombination repair mutations. J Clin Oncol. 2023;14(16_suppl). doi:10.1200/JCO.2023.41.16_suppl.e17053

ABOUT THE EXPERTS

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement